Genmab Reaches Milestone in Janssen Daratumumab Pact

Genmab has reached the first milestone in its daratumumab collaboration with Janssen Biotech, Inc., triggering an $8 million milestone payment from Janssen based on progress in the clinical development of daratumumab.

“Since the inception of our agreement with Janssen, we have reported encouraging data from two clinical studies of daratumumab and have started one new study. We are pleased to reach the first milestone in this productive collaboration and look forward to making further progress with daratumumab,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab.